GlassScriptPhysician profile
Stephen D Schlinke
NPI 1801861166
$3,370.31
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $239 · 2021: $1,206 · 2022: $715 · 2023: $572 · 2024: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $514.97 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $414.01 | 2020-2024 | Trulance, Xifaxan |
| Astellas Pharma US INC | $358.38 | 2019-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $171.62 | 2021-2023 | |
| Avion Pharmaceuticals | $171.12 | 2019-2023 | Balcoltra |
| Therapeuticsmd, INC. | $170.95 | 2019-2021 | |
| Pfizer INC. | $141.90 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $139.49 | 2023-2024 | Gemtesa |
| Mayne Pharma Commercial LLC | $136.25 | 2022-2024 | |
| Exeltis, USA INC. | $119.32 | 2019-2024 | Slynd |
| Urovant Sciences INC | $99.85 | 2021-2022 | |
| Coloplast Corp | $90.26 | 2019-2023 | Saffron |
| Roche Diagnostics Corporation | $83.53 | 2019 | |
| Merck Sharp & Dohme LLC | $79.19 | 2021-2023 | Gardasil 9 |
| Lupin INC. | $76.57 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $67.25 | 2020-2024 | Intrarosa, Femring |
| Boston Scientific Corporation | $63.75 | 2019-2021 | |
| Hologic Sales and Service, LLC | $56.42 | 2021-2024 | Aptima, Thinprep 2000 Processor, Novasure |
| Medtronic, INC. | $51.10 | 2021-2022 | |
| Evofem Biosciences, INC. | $50.85 | 2020-2021 | |
| Meditrina | $47.37 | 2023-2024 | |
| Allergan, INC. | $43.39 | 2019-2020 | |
| Axonics, INC. | $41.58 | 2020-2023 | Bulkamid |
| Myriad Women'S Health, INC. | $39.45 | 2023 | Myrisk |
| Scynexis, INC. | $37.61 | 2022 | |
| Kerecis Limited | $19.36 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Mission Pharmacal Company | $16.71 | 2020 | |
| Agile Therapeutics, INC. | $16.67 | 2022 | |
| Minerva Surgical, INC | $13.76 | 2023 | |
| Sage Therapeutics, LLC | $13.45 | 2021 | |
| Mylan Pharmaceuticals INC. | $13.21 | 2021 | |
| Amag Pharmaceuticals, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Schlinke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.